IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
IceCure Medical (NASDAQ: ICCM) said its U.S. active commercial install base for its ProSense breast cancer cryoablation system rose 70% after FDA marketing authorization in October 2025. The company attributed growth to expanding physician demand, clinical guideline support (ASBrS resource guide), and increased patient awareness, including Reuters and local TV coverage.
How this was made
The 30-second read
Why it matters
The company links FDA clearance to accelerating physician demand and clinical acceptance, citing a 70% increase in U.S. active commercial install base and higher sales leads at major breast-health conferences.
Market read
A concrete, post-clearance commercial adoption metric (70% install-base growth) provides a fresh catalyst for ICCM positioning, though it stops short of revenue guidance.
What to watch
No disclosure of unit economics, reimbursement dynamics, competitive intensity, or whether the 70% figure reflects net new systems vs. reactivation/definition changes.
Background
IceCure’s ProSense cryoablation system received FDA marketing authorization in October 2025; this PR highlights post-authorization commercial adoption in the U.S.
Ticker impact
IceCure says FDA marketing authorization (Oct 2025) drove a 70% rise in its U.S. active commercial install base for ProSense systems.
Near-term bias to the upside on continued adoption/lead-generation; magnitude depends on whether investors view this as durable revenue conversion.
The release provides a specific post-clearance metric (70% active commercial install base) plus supporting demand drivers (physician leads at SBI/ASBrS, updated ASBrS guidance, media visibility). However, it does not quantify revenue, margins, or procedure volumes, limiting precision on earnings impact.
Market effects
Supports read-across that FDA-cleared minimally invasive oncology devices can gain faster adoption when clinical guidelines and physician education align.
Primarily U.S. commercial footprint expansion; may modestly lift sentiment around U.S. breast-care procedure ecosystems.
U.S. traction could improve investor confidence in global commercialization, but the disclosed metric is U.S.-specific.
Counterpoint
Install-base growth may not fully translate into revenue/procedure volume; early adoption can be lumpy and dependent on reimbursement and training ramp.
Key entities
- companyIceCure Medical Ltd.
Subject of the press release; reports 70% growth in U.S. active commercial install base for ProSense after FDA authorization.
- productProSense® Cryoablation System
FDA-authorized device for local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70+.
- regulatorU.S. Food and Drug Administration (FDA)
Granted marketing authorization in October 2025, which the company cites as the catalyst for adoption.
- clinical guidelineASBrS Resource Guide
Updated to recommend cryoablation as a local treatment option for low-risk breast cancer patients.
